Article
Pharmacology & Pharmacy
Kenneth Chappell, Abd El Kader Ait Tayeb, Romain Colle, Jerome Bouligand, Khalil El-Asmar, Florence Gressier, Severine Trabado, Denis Joseph David, Bruno Feve, Laurent Becquemont, Emmanuelle Corruble, Celine Verstuyft
Summary: This study found that genetic variants of ARRB1 may influence the response to antidepressant drug treatment in depressed patients. The analysis of rare variants showed significant associations with changes in HDRS scores and remission. The results suggest that beta-arrestin 1 and genetic variants of ARRB1 may serve as useful clinical biomarkers for clinical improvement following antidepressant drug treatment in depressed individuals.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Chemistry, Medicinal
Win Lee Edwin Wong, Chiara Fabbri, Benjamin Laplace, Danyang Li, Roos van Westrhenen, Cathryn M. Lewis, Gavin Stewart Dawe, Allan H. Young
Summary: This study suggests that CYP2C19 genotypes, and consequently metabolic phenotypes, may play a role in determining clinical responses to SSRIs, particularly escitalopram and citalopram. However, further investigation is needed to better understand this relationship.
Article
Clinical Neurology
Kenneth Chappell, Romain Colle, Abd El Kader Ait Tayeb, Jerome Bouligand, Khalil El-Asmar, Eric Deflesselle, Bruno Feve, Laurent Becquemont, Emmanuelle Corruble, Celine Verstuyft
Summary: This study found an association between the ERICH3 rs11580409 genetic polymorphism and treatment response following long-term antidepressant medication. The rs11580409 polymorphism may serve as a useful biomarker for treatment response in major depressive disorder.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2022)
Article
Health Care Sciences & Services
Kiera Stein, Abdullah Al Maruf, Daniel J. Mueller, Jeffrey R. Bishop, Chad A. Bousman
Summary: Carriers of the 5-HTTLPR LL or LS genotypes were more likely to respond to antidepressant therapy, and relative to SS carriers, long (L) allele carriers taking SSRIs reported fewer ADRs.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Clinical Neurology
Julia J. Meerman, Sophie E. ter Hark, Joost G. E. Janzing, Marieke J. H. Coenen
Summary: This review examines the genetic overlap between various traits and antidepressant treatment response in patients with unipolar MDD using polygenic risk scores (PRS). The results suggest that PRSs for several traits, including attention-deficit hyperactivity disorder and coronary artery disease, may be associated with antidepressant treatment response. However, the studies varied in sample size and outcome measures, highlighting the need for larger cohorts and standardized assessment methods.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Clinical Neurology
Priyanka Singh, Ankit Srivastava, Debleena Guin, Sarita Thakran, Jyoti Yadav, Puneet Chandna, Mamta Sood, Rakesh Kumar Chadda, Ritushree Kukreti
Summary: This study reviewed all genetic association findings related to major depressive disorder (MDD) susceptibility and antidepressant response and identified replicated variants that have the potential to be used for disease diagnosis and improved treatment outcomes.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
(2023)
Article
Health Care Sciences & Services
Taichi Ochi, Natalya M. Vyalova, Innokentiy S. Losenkov, Diana Z. Paderina, Ivan Pozhidaev, Anton J. M. Loonen, German G. Simutkin, Nikolay A. Bokhan, Bob Wilffert, Svetlana A. Ivanova
Summary: This study found a possible association between genotype related to dopamine neurotransmission and antidepressant treatment response. DRD4 and MAOB genotypes were linked to improved HAMD 17 scores, but the preliminary nature of the results is noted due to the limited sample size. Further research into the role of habenular dopamine D4 receptors in antidepressant response is recommended.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Ping Siu Kee, Simran D. S. Maggo, Martin A. Kennedy, Paul K. L. Chin
Summary: Pharmacogenetics has the potential to optimize the use of psychotropic drugs, specifically in the prescribing of antidepressants. This study evaluated the clinical usefulness of genotyping CYP2D6 and CYP2C19 in antidepressant response using data from patients who experienced adverse reactions or ineffectiveness. The results showed that the genotypes of CYP2D6 and CYP2C19 were actionable in 38% of the antidepressant-response pairs, with a higher percentage related to adverse reactions.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Genetics & Heredity
Milica Radosavljevic, Dubravka Svob Strac, Jasna Jancic, Janko Samardzic
Summary: Pharmacotherapy for neuropsychiatric disorders, such as anxiety and depression, is highly variable among individuals and often results in side effects. Pharmacogenetics, as a part of personalized medicine, aims to optimize therapy by targeting genetic variations involved in drug metabolism and efficacy. Recent studies have shown that genotype-guided decisions can improve the effectiveness and safety of antidepressant and anxiolytic treatments. Additionally, the emerging field of pharmacoepigenetics investigates how epigenetic mechanisms may influence individual drug responses. Understanding the epigenetic variability of patients' response to pharmacotherapy can lead to the selection of more effective drugs and minimize adverse reactions, ultimately improving treatment outcomes.
Article
Pharmacology & Pharmacy
Maike Scherf-Clavel, Heike Weber, Catherina Wurst, Saskia Stonawski, Leif Hommers, Stefan Unterecker, Christiane Wolf, Katharina Domschke, Nicolas Rost, Tanja Brueckl, Susanne Lucae, Manfred Uhr, Elisabeth B. Binder, Andreas Menke, Juergen Deckert
Summary: The study found that PK gene variation can predict serum concentrations, and the combination of pharmacogenetic testing and therapeutic drug monitoring is a useful tool in a personalized therapy approach for depression.
PHARMACOPSYCHIATRY
(2022)
Article
Genetics & Heredity
Malcolm Forbes, Mal Hopwood, Chad A. Bousman
Summary: Pharmacogenomic testing for antidepressant medication selection and dosing is gaining attention in Australia. This study evaluated the coverage of CYP2D6 and CYP2C19 variants in commercial antidepressant PGx testing panels in Victoria. The findings suggest that current PGx tests may not be suitable for all individuals due to limited coverage of CYP2D6 variants.
Review
Pharmacology & Pharmacy
Bradley Roberts, Zahra Cooper, Stephanie Lu, Susanne Stanley, Bernadette T. Majda, Khan R. L. Collins, Lucy Gilkes, Jennifer Rodger, P. Anthony Akkari, Sean D. Hood
Summary: Pharmacogenetics (PGx) studies how individual genetic differences can affect drug responses. PGx testing can individualize primary care and provide a safer drug prescription model. It has shown promising evidence in improving drug efficacy and reducing toxicity in psychiatry. However, there are barriers hindering its implementation.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Kenneth Chappell, Romain Colle, Jerome Bouligand, Severine Trabado, Bruno Feve, Laurent Becquemont, Emmanuelle Corruble, Celine Verstuyft
Summary: Genetic variants in the MAOA and MAOB genes are associated with clinical improvement and plasma 5HIAA/5HT ratio in patients treated with antidepressant drugs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Duan Liu, Yongxian Zhuang, Lingxin Zhang, Huanyao Gao, Drew Neavin, Tania Carrillo-Roa, Yani Wang, Jia Yu, Sisi Qin, Daniel C. Kim, Erica Liu, Thanh Thanh Le Nguyen, Joanna M. Biernacka, Rima Kaddurah-Daouk, Boadie W. Dunlop, W. Edward Craighead, Helen S. Mayberg, Elisabeth B. Binder, Mark A. Frye, Liewei Wang, Richard M. Weinshilboum
Summary: ERICH3 gene may play a significant role in vesicular function in serotonergic and other neuronal cell types, which could help explain its association with plasma serotonin concentrations and SSRI clinical response.
MOLECULAR PSYCHIATRY
(2021)
Article
Rheumatology
Nerea Alonso, Omar M. E. Albagha, Asim Azfer, Beatriz Larraz-Prieto, Kathryn Berg, Philip L. Riches, Barbara Ostanek, Tomaz Kocjan, Janja Marc, Bente L. Langdahl, Stuart H. Ralston
Summary: This study identified genetic variants that are associated with the response to teriparatide (TPTD) in osteoporosis patients. A variant near the CXCR4 gene on chromosome 2 was found to be significantly associated with the response of spine bone mineral density (BMD) to TPTD. Another variant on chromosome 19 was associated with the response of femoral neck BMD to TPTD. These findings suggest that genetic factors play a role in the individual response to TPTD in osteoporosis patients.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Psychology, Clinical
Chiara Fabbri, Julian Mutz, Cathryn M. Lewis, Alessandro Serretti
Summary: This study was the first to comprehensively evaluate the predictors of wellbeing in relation to the history of MDD. The identified variables are important to identify individuals at risk and promote wellbeing.
PSYCHOLOGICAL MEDICINE
(2023)
Editorial Material
Neurosciences
Dekel Taliaz, Alessandro Serretti
Summary: The validity of clinical trials in psychiatry has been under discussion in the past two decades. The commonly used method of randomized controlled trials (RCTs) faces challenges when applied in the psychiatric field due to strict participant criteria and inconsistency in endpoint parameters. This has led to problematic clinical practice in psychiatry.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
(2023)
Article
Psychiatry
Helle Nystrup Lund, Inge Nygaard Pedersen, Agnieszka M. Heymann-Szlachcinska, Maryla Tuszewska, Gustav Bizik, Jens Ivar Larsen, Antonio Drago, Eszter Kulhay, Anelia Larsen, Helle Ostermark Sorensen, Bettina Gronbech, Lars Rye Bertelsen, Jan Brink Valentin, Jan Mainz, Soren Paaske Johnsen
Summary: This study examined the efficacy of music intervention in depression-related insomnia. The results showed that music intervention can significantly improve sleep quality and well-being. However, the effects of music intervention decreased after the intervention was terminated.
NORDIC JOURNAL OF PSYCHIATRY
(2023)
Article
Pharmacology & Pharmacy
Vincenzo Oliva, Giuseppe Fanelli, Manuel Zamparini, Cristina Zarbo, Matteo Rocchetti, Letizia Casiraghi, Fabrizio Starace, Alessandra Martinelli, Alessandro Serretti, Giovanni de Girolamo, DiAPASon Consortium
Summary: Antipsychotic polypharmacy (APP) is commonly used in patients with schizophrenia spectrum disorders (SSDs) despite recommendations against it. This study found high rates of APP and lower levels of physical activity in both residential and outpatient patients. However, patients on APP showed trends of reduced sedentariness and higher levels of light physical activity compared to those on monopharmacy.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
(2023)
Review
Psychiatry
Kristina Mozuraityte, Agne Stanyte, Naomi A. Fineberg, Alessandro Serretti, Julija Gecaite-Stonciene, Julius Burkauskas
Summary: This study conducted a scoping review of published literature to examine the relationship between mental fatigue and various psychiatric disorders. The findings suggest that mental fatigue is studied in mood disorders, anxiety disorders, obsessive-compulsive disorder, and obsessive-compulsive personality disorder. Cognitive factors such as unhelpful beliefs about sleep and symptom-focussed rumination, as well as personality risk factors, were found to be relevant in predicting mental fatigue symptoms. Further investigation is needed to explore mental fatigue in adult psychiatric samples.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
(2023)
Article
Psychiatry
Fabio Panariello, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Panagiotis Ferentinos, Dan Rujescu, Julien Mendlewicz, Diana De Ronchi, Alessandro Serretti, Chiara Fabbri
Summary: This study aimed to identify factors associated with side effects of psychotropic drugs in a real-world setting enriched with treatment-resistant depression (TRD) patients. Results showed that the severity of depressive symptoms was associated with total, psychic, and neurological side effects, while autonomic side effects were higher in patients with somatic comorbidities and lower in patients receiving trazodone. Multivariate analyses revealed that depressive symptom severity was associated with psychic and total side effects, generalized anxiety disorder (GAD) with neurological side effects, and somatic comorbidities remained associated with autonomic side effects. Trazodone was associated with lower side effects and with augmentation treatments. Augmentation therapies showed opposite effects depending on response status, i.e. increased or decreased the risk of side effects in responders and non-responders/resistant patients, respectively.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
(2023)
Article
Clinical Neurology
Vincenzo Oliva, Giuseppe Fanelli, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Diego Albani, Gianluigi Forloni, Panagiotis Ferentinos, Dan Rujescu, Julien Mendlewicz, Diana De Ronchi, Chiara Fabbri, Alessandro Serretti
Summary: This study found that different clinical subtypes of major depressive disorder (MDD), particularly melancholic features and typical neurovegetative symptoms, may be associated with distinct underlying genetics. These findings contribute to a better understanding of the genetic heterogeneity of MDD.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Review
Genetics & Heredity
Raffaella Zanardi, Matteo Carminati, Francesco Attanasio, Chiara Fabbri, Alessandro Serretti
Summary: Nonpharmacological treatments for depression show effectiveness and tolerability in certain patients with diverse response. Genetic variables associated with treatment efficacy need to be examined to assist treatment selection. Most studies using candidate gene approach yielded poorly replicated findings due to small sample sizes, while a few methylome-wide and genome-wide association studies (GWASs) provided interesting results with the use of polygenic risk scores in small samples of electroconvulsive therapy (ECT) and cognitive-behavioral therapy. Further GWAS with larger sample sizes, such as the gen-ECT-ic consortium, can enhance our understanding of the genetic factors underlying treatment response in nonpharmacological therapies for depression.
PSYCHIATRIC GENETICS
(2023)
Editorial Material
Pharmacology & Pharmacy
Paolo Olgiati, Alessandro Serretti
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
(2023)
Editorial Material
Pharmacology & Pharmacy
Alessandro Serretti
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
(2023)
Review
Neurosciences
Alessandro Serretti
Summary: Anhedonia is a core symptom of depression and other psychiatric disorders, referring to a lack of pleasure or reward. It is not only a psychological distress but also encompasses a range of reward processing deficits. Anhedonia is a relevant risk factor for suicidal behaviors and may operate independently of the severity of depressive episodes. It has also been associated with inflammation, which can have a reciprocal detrimental effect on depression. The neurophysiological bases of anhedonia mainly involve changes in striatal and prefrontal areas, with dopamine playing a key role as the neurotransmitter involved. Anhedonia is believed to have a significant genetic component and polygenic risk scores may be a tool for predicting an individual's risk for developing anhedonia. Traditional antidepressants have shown limited benefit in treating anhedonia, also considering their potential to worsen anhedonia in some individuals. Other treatments such as agomelatine, vortioxetine, ketamine, and transcranial magnetic stimulation may be more effective. Psychotherapy, particularly cognitive-behavioral therapy and behavioral activation, is widely supported as beneficial for anhedonia. In conclusion, evidence suggests that anhedonia is partially independent from depression and requires careful evaluation and targeted treatment.
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE
(2023)
Article
Psychiatry
Alexander Kautzky, Lucie Bartova, Gernot Fugger, Markus Dold, Daniel Souery, Stuart Montgomery, Joseph Zohar, Julien Mendlewicz, Chiara Fabbri, Alessandro Serretti, Dan Rujescu, Siegfried Kasper
Summary: This study investigates the differences in presentation and treatment outcomes of treatment-resistant depression (TRD) among different age groups. It finds that age has an impact on depressive symptoms and treatment outcomes. In TRD patients, symptom load and hospitalization time increase with age, while treatment responders do not show this trend. Older patients are more likely to have symptoms such as inner tension, reduced appetite, concentration difficulties, and lassitude.
EUROPEAN PSYCHIATRY
(2023)
Meeting Abstract
Psychiatry
M. Calabro, C. Crisafulli, A. Drago
EUROPEAN PSYCHIATRY
(2023)
Meeting Abstract
Psychiatry
H. N. Lund, I. N. Pedersen, A. Heymann-Szlachcinska, M. Tuszewska, G. Bizik, J. I. Larsen, A. Drago, E. Kulhay, A. Larsen, H. O. Sorensen, B. Gronbech, L. R. Bertelsen, J. B. Valentin, J. Mainz, S. P. Johnsen, N. Hannibal, R. MacDonald
EUROPEAN PSYCHIATRY
(2023)
